Astellas : News Releases

Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025

27 days ago

- New clinical data across ten accepted abstracts demonstrate significant progress across...

Astellas Announces Top Management Personnel Change

29 days ago

TOKYO, Sep 29, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Embracing Communities of Innovation: Massachusetts

about 1 month ago

Astellas Receives Conditional Approval for IZERVAY, making it the first and only approved treatment for the Suppression of Geographic Atrophy Growth in Japan

about 1 month ago

TOKYO, Sep 19, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

PADCEVTM Plus KEYTRUDATM Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

3 months ago

PADCEV plus KEYTRUDA is the first and only regimen to improve survival...

Posted Financial Results for Q1 YTD/FY2025

3 months ago

Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of a Korean Government Agency, for the Operation of the“Partnership with Global Companies Program”

3 months ago

- Supporting Korean Startups’ Drug Discovery Research and Global Expansion -- First...

Sales of IZERVAY™ (Preliminary Figures)

4 months ago

TOKYO, July 10, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

5 months ago

Tokyo, 13 June 2025—Mitsubishi Research Institute, Inc. (“MRI”) and Astellas Pharma Inc...

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2

5 months ago

- Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong...

Posted Notice of Convocation of the 20th Term Annual Shareholders Meeting

5 months ago

Shaping the Future with Pompe Patients

5 months ago